Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

25-May-2012 - Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financial ...

Roche and Alnylam form major alliance on RNAi therapeutics

Alnylam to receive 331 million US dollars in upfront payments and equity investment

10-Jul-2007 - Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics. The alliance will initially ...

Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market

03-Apr-2007 - Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in ...

Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics

29-Nov-2006 - Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced that a key patent was issued by the United States Patent and Trademark Office (USPTO). The U.S. patent (No. 7,138,517 or " '517 patent") broadly covers certain chemical modifications of oligonucleotides used to introduce ...

Alnylam Grants Integrated DNA Technologies License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market

02-Mar-2006 - Alnylam Pharmaceuticals, Inc. and Integrated DNA Technologies, Inc. (IDT), supplier of custom nucleic acids in the U.S., announced that Alnylam has granted IDT a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned ...

Alnylam Grants Dharmacon License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market

09-Jan-2006 - Alnylam Pharmaceuticals, Inc. and Dharmacon, Inc., a business unit of the Fisher Biosciences group, announced that Alnylam has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned solely by ...

Novartis and Alnylam Create Major Alliance to Discover RNAi Therapeutics

09-Sep-2005 - Novartis and Alnylam Pharmaceuticals, Inc. announced a major multi-year alliance focused on the discovery of innovative therapeutics based on RNA interference (RNAi). The alliance will combine the research expertise and understanding of disease mechanism and pathway biology of Novartis with ...

Alnylam Receives Allowance for Broad New European Patent Covering RNAi Therapeutics

New "Kreutzer-Limmer II'' Patent Covers RNAi Therapeutics towards over 125 Disease Targets

12-Aug-2005 - Alnylam Pharmaceuticals, Inc. announced the allowance of broad claims from the European Patent Office for a new patent (EP Patent No. 1352061) covering small interfering RNAs (siRNAs), the molecules that mediate RNA interference (RNAi). The new "Kreutzer-Limmer II" patent, which Alnylam acquired ...

Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications in the Research Products Market

26-Jul-2005 - Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has granted MWG Biotech AG a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers ...

Alnylam Grants Ambion License to Fundamental RNAi Patents for Applications in the Research Products Market

13-Jun-2005 - Alnylam Pharmaceuticals, Inc. announced that it has granted Ambion, Inc. a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use ...